Scandium-47
Why Scandium-47?
Scandium-47 (Sc-47) is a "true" theranostic, a single nuclide capable of delivering targeted therapy and high-resolution diagnostic imaging simultaneously.
-
Targeted Beta Therapy: Medium-energy β⁻ emission optimized for destroying small-to-medium tumors while sparing healthy tissue.
-
Direct SPECT Imaging: Its 159 keV gamma peak is nearly identical to Technetium-99m, ensuring seamless compatibility with standard hospital SPECT cameras.
-
The Sc-44/47 Matched Pair: Identical chemistry to Scandium-44 (PET) allows the exact same drug to be used for both diagnosis and therapy, ensuring absolute dose precision.
-
Strategic Logistics: A 3.35-day half-life provides the ideal "Goldilocks" window for nationwide distribution and effective tumor clearance.
Technical Snapshot
Isotope: Scandium-47 (Sc-47)
Half-life: ~3.35 days
Decay Mode: Beta emission (Therapy) & Gamma emission (Imaging)
Key Reaction: Ti-48(γ,p) → Sc-47 or
Ca-48(γ,n) → Ca-47 → Sc-47
Primary Use: Emerging Theranostic (Targeted Radionuclide Therapy + SPECT)
The Challenge: Unlocking a Rare Isotope
Despite its immense scientific appeal, Scandium-47 is not yet widely commercialised due to a supply bottleneck. Currently, there is no established, large-scale global supply chain for high-purity, no-carrier-added Sc-47.
-
Production Scarcity: Traditional reactor-based methods often struggle to produce the high specific activity required for effective targeted therapies.
-
Early-Stage Market: While isotopes like Lutetium-177 are now global standards, Sc-47 remains in the "developing" phase, waiting for a reliable, scalable production technology to bring it into routine clinical trials.
The SCMR Solution: Next-Generation Accelerator Production
When SCMR develops high-power electron accelerator capability, it is uniquely suited to overcome the Scandium supply challenge. By leveraging the same "photonuclear" technology used for our Actinium-225 and Copper-67 programs, we are evaluating a reactor-free pathway to Sc-47.
-
Photonuclear Innovation: By using high-energy bremsstrahlung photons to knock protons or neutrons out of enriched Titanium or Calcium targets, SCMR can produce high-purity Sc-47 without the need for a nuclear reactor.
-
Infrastructure Versatility: Because our accelerators are designed for high-power, multi-isotope runs, Scandium-47 can be integrated into our production cycles as a future-facing therapeutic offering.
-
Sovereign Innovation: By developing Sc-47 capability in Australia, SCMR positions the nation at the forefront of the next wave of radiopharmaceutical research, moving beyond current standards into the next generation of cancer care.
Verdict: The Future of Precision Oncology
While Actinium-225 remains our high-impact priority for Targeted Alpha Therapy, Scandium-47 represents the future of matched-pair theranostics. By including Sc-47 in our developmental pipeline, SCMR demonstrates a long-term commitment to innovation.
SCMR is establishing the foundational infrastructure required to support the next generation of cancer therapies. By securing the production of emerging isotopes today, we ensure Australia remains a permanent fixture at the forefront of the global nuclear medicine landscape